Breast Cancer Res Treat Archives

Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics
Gallery
Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics

Evidence, MammaPrint, Other, Validation

Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics

PUBLICATION: Breast Cancer Res Treat (2016) 156: 279. https://doi.org/10.1007/s10549-016-3764-5 AUTHORS: Read More

kevin2024-03-25T09:21:49-07:00March 22nd, 2016|Evidence, MammaPrint, Other, Validation|

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
Gallery
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

BluePrint, Evidence, Other

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Read More

kevin2024-03-25T09:23:03-07:00November 1st, 2015|BluePrint, Evidence, Other|

Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis
Gallery
Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis

Adjuvant, Evidence, MammaPrint

Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis

PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: Read More

kevin2024-03-25T09:27:24-07:00November 24th, 2014|Adjuvant, Evidence, MammaPrint|

Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms
Gallery
Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

Adjuvant, Evidence, MammaPrint, RASTER

Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub Read More

kevin2024-03-25T10:21:40-07:00June 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|

Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers
Gallery
Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers

Adjuvant, Evidence, MammaPrint, MINDACT, Other

Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers

PUBLICATION: Breast Cancer Res Treat. 2014 Feb;144(1):103-11. doi: 10.1007/s10549-013-2830-5. Epub Read More

kevin2024-03-25T10:25:05-07:00February 2nd, 2014|Adjuvant, Evidence, MammaPrint, MINDACT, Other|

Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome
Gallery
Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome

Adjuvant, Evidence, MammaPrint, Other, Validation

Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome

PUBLICATION: Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub Read More

kevin2024-03-25T10:40:13-07:00February 1st, 2014|Adjuvant, Evidence, MammaPrint, Other, Validation|

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

Adjuvant, BluePrint, Evidence

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Read More

kevin2024-03-25T10:44:00-07:00August 4th, 2013|Adjuvant, BluePrint, Evidence|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

BluePrint, Evidence, Neoadjuvant

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Read More

kevin2024-03-25T10:46:58-07:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
Gallery
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

Evidence, Healthcare Economics, MammaPrint, Other

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More

kevin2024-03-25T10:47:25-07:00June 1st, 2013|Evidence, Healthcare Economics, MammaPrint, Other|

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

Evidence, Lobular, MammaPrint, Neoadjuvant, Other

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More

kevin2024-03-25T10:51:13-07:00November 1st, 2012|Evidence, Lobular, MammaPrint, Neoadjuvant, Other|